(CercleFinance.com) – Novartis announces that its Tafinlar-Mekinist combination has demonstrated ‘unprecedented efficacy’ in patients aged one to 17 years with BRAF V600 low-grade pediatric glioma requiring initial systemic therapy, compared to chemotherapy.
In a phase II/III study, patients randomized to receive Tafinlar + Mekinist had a statistically significant overall response rate (ORR) of 47%, compared with 11% for those randomized to receive chemotherapy.
‘Additional results showed that after a median follow-up of 18.9 months, the median progression-free survival (PFS) was 20.1 months with Tafinlar+Mekinist, compared to 7.4 months with chemotherapy,’ adds the group. Swiss pharmaceutical.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
